Модуляторы Нейронального Кальциевого Сигналинга – Перспективные Фармакологические Агенты Для Лечения Патогенетических Форм Болезни Альцгеймера

Попугаева, Елена; Чернюк, Д. П.; Zernov, Nikita; Безпрозванный, И. Б.

doi:10.31857/s0044452920072279

Cited by 1 publication

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Тем не менее испытания лекарств, нацеленных на амилоид β, в большинстве случаев оказались безуспешными. На сегодняшний день многие исследования показали, что Ca2+-дисгомеостаз и потеря синапсов являются ранним событием, лежащим в основе цитотоксичности нейронов, и возникают раньше, чем отложение бляшек и нейрофибриллярных клубочков [24][25][26][27][28]. Двухлетнее наблюдение за пациентами, принимаю щими различные блокаторы кальциевых каналов, показало снижение риска развития деменции, психотических и аффективных расстройств [29].…”

Section: когнитивные расстройстваunclassified

Substantiated therapy of pre-dementia cognitive impairment with calcium-channel blockers

Zhitkova

2023

Medicinskij sovet

View full text Add to dashboard Cite

Pre-dementia cognitive impairments are a significant part of a cognitive impairment range, considered the most perspective in terms of conversion into dementia prevention. At the same time pre-dementia cognitive impairment treatment presents certain difficulties in connection with the absence of precise medicinal strategies with the high evidence level. According to current clinical recommendations, the priority in cognitive pre-dementia treatment lies in the correction of modifiable risk factors of cognitive impairment progression and non-drug therapy methods. Nevertheless, there is a great need in receiving the proofs of pathogenetically justified use of drugs with a potentially effective mechanism of action. Universal and early pathogenetical mechanism of many diseases of central nervous system, leading to the development of cognitive impairments, including Alzheimer’s disease, is Ca2+ dyshomeostasis. In this connection, the use of drugs, regulating Ca2+ metabolism in neurons in treatment of patients with pre-dementia cognitive impairments, especially high brain penetrance drugs, is potentially well-grounded. The article gives the data review of modern researches, studying the efficiency and safety of nimodipin a selective Ca+ channel blocker of the 2 class. The article provides examples of the use of nimodipin in treatment and prevention of pre-dementia syndroms of various genesis: Alzheimer’s disease, chronic brain hypoperfusion damage, post-radiation and postoperative cognitive dysfunction, etc. The article presents experimental data about nimodipin use in the prevention of postoperative delirium in elderly people and in the treatment of non-cognitive neurological disorders. Justification of the perspectives of the application area extension and directions for the further research of nimodipin are as well given in the article.

show abstract

Section: когнитивные расстройстваunclassified

Substantiated therapy of pre-dementia cognitive impairment with calcium-channel blockers

Zhitkova

2023

Medicinskij sovet

View full text Add to dashboard Cite

show abstract

Модуляторы Нейронального Кальциевого Сигналинга – Перспективные Фармакологические Агенты Для Лечения Патогенетических Форм Болезни Альцгеймера

Cited by 1 publication

References 0 publications

Substantiated therapy of pre-dementia cognitive impairment with calcium-channel blockers

Substantiated therapy of pre-dementia cognitive impairment with calcium-channel blockers

Contact Info

Product

Resources

About